Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million

2 days ago 5

Jonathan Ponciano, The Motley Fool

Mon, May 18, 2026 astatine 10:19 AM CDT 4 min read

SB Investment Advisers (UK) Ltd reported a merchantability of 2,168,884 shares of Vir Biotechnology (NASDAQ:VIR) successful its May 15, 2026, SEC filing, an estimated $17.28 cardinal commercialized based connected quarterly mean pricing.

What happened

According to an SEC filing dated May 15, 2026, SB Investment Advisers (UK) Ltd reduced its involvement successful Vir Biotechnology by 2,168,884 shares during the archetypal quarter. The estimated worth of the shares sold was $17.28 million, calculated utilizing the mean unadjusted closing terms for the quarter. The quarter-end worth of the position, including marketplace movements, declined by $19.00 million.

What other to cognize

Top holdings aft the filing:
- NYSE:CPNG: $5.47 cardinal (70.7% of AUM)
- NASDAQ: GRAB: $1.47 cardinal (19.0% of AUM)
- NASDAQ: RLAY: $277.65 cardinal (3.6% of AUM)
- NYSE: COMP: $160.85 cardinal (2.1% of AUM)
- NASDAQ:VIR: $98.09 cardinal (1.3% of AUM)
As of May 15, 2026, Vir Biotechnology shares were priced astatine $8.79, up 93% implicit the past twelvemonth and outperforming the S&P 500’s astir 25% summation successful the aforesaid period.

Company overview

Metric

Value

Price (as of marketplace adjacent 2026-05-15)	$8.79
Market Capitalization	$1.48 billion
Revenue (TTM)	$64.7 million
Net Income (TTM)	($442.72 million)

Company snapshot

Vir Biotechnology develops monoclonal antibodies and RNA-based therapeutics targeting infectious diseases, including COVID-19 (Sotrovimab/Xevudy), hepatitis B (VIR-2218, VIR-3434), influenza A (VIR-2482), and HIV (VIR-1111).
The steadfast operates a research-driven concern model, generating gross done merchandise sales, strategical collaborations, and licensing agreements with planetary pharmaceutical and biotechnology partners.
It serves healthcare providers, governments, and planetary wellness organizations focused connected the attraction and prevention of superior infectious diseases.

Vir Biotechnology, Inc. is simply a commercial-stage biotechnology institution specializing successful the improvement of innovative immunology-based therapies for infectious diseases. The institution leverages strategical collaborations and precocious probe capabilities to code unmet aesculapian needs successful planetary health. Its diversified pipeline and partnerships with starring institutions presumption it for imaginable semipermanent maturation successful the biotechnology sector.

What this transaction means for investors

This merchantability yet looks much similar portfolio absorption aft a crisp tally than a afloat retreat from the story. Even aft trimming much than 2 cardinal shares, Vir Biotechnology inactive remained 1 of SB Investment Advisers’ larger healthcare bets astatine astir $98 million, suggesting the steadfast whitethorn inactive spot semipermanent upside successful the company’s oncology and hepatitis pipeline.

The bigger communicative for investors is that Vir is evolving good beyond its pandemic-era identity. Management spent overmuch of its latest net update emphasizing oncology progress, peculiarly its concern with Astellas astir prostate crab cause campaigner VIR-5500. The institution said the collaboration officially closed during the 4th and that the archetypal diligent has already been dosed successful enlargement cohorts.

Meanwhile, Vir besides continues advancing its hepatitis delta program, wherever updated Phase 2 information showed 77% of patients achieved undetectable microorganism levels astatine Week 72, with immoderate cohorts improving to 88% done Week 96. The institution ended the 4th with $809.3 cardinal successful currency and investments, excluding different $315 cardinal expected from Astellas.

Read Entire Article